MediciNova – About the Company
MediciNova (NasdaqGM: MNOV; TYO: 4875) is a clinical-stage biopharmaceutical company developing treatments for neurological and fibrotic diseases with unmet medical needs. The Company is currently testing its lead compound MN-166 in a Phase IIb study for the treatment of progressive forms of multiple sclerosis (MS). In contrast to the treatment of relapsing-remitting MS (RRMS), there are no approved therapies for progressive MS and few drugs in development aside from MN-166 that have been shown to slow disability progression in a clinical study. MediciNova is also conducting Phase II studies to evaluate MN-001, an inhibitor of multiple inflammatory and fibrotic pathways, as a therapy for non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).